Hypertension is believed to be the single greatest factor influencing the development of heart failure, particularly heart failure with preserved ejection fraction, also known as diastolic heart ...

Cardiomyopathy is the leading cause of mortality in patients with DMD. Compared with their healthy counterparts, patients with DMD — including those with preserved left ventricular ejection fraction ...

Whether revascularization by percutaneous coronary intervention (PCI) can improve event-free survival and left ventricular function in patients with severe ischemic left ventricular systolic ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

A less invasive test commonly used to diagnose coronary disease also may be used to detect one of the leading causes of heart failure, say researchers at the Medical College of Georgia. By using a ...

Measurement – the Gold Standard for Heart Failure Diagnosis – Previously Only Obtainable Via Invasive Procedures PASADENA, Calif.--(BUSINESS WIRE)--#cardiology--Ventric Health, a medtech innovator ...

A recent study found that Sodium-glucose co-transporter 2 (SGLT2) inhibitors use in hypertrophic cardiomyopathy (HCM) ...

Cytokinetics has announced that the FDA has approved MYQORZO tablets in 5mg, 10mg, 15mg, and 20mg doses for adults with oHCM .

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.